Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 3:57 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 172 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Postprandial Glucose Clear all

Conditions: Pregnancy Related, Stress, Psychological, Glucose Intolerance During Pregnancy, Emotional Stress, Postprandial Hyperglycemia, Insulin Sensitivity/Resistance
Interventions: Psychosocial stress, Control non-stress; Behavioral
Lead sponsor: University of California, Irvine; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 113 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 2
States / cities: Irvine, California • Orange, California

Conditions: Diabetes Mellitus
Interventions: Insulin (recombinant human insulin), NovoLog; Drug
Lead sponsor: Nastech Pharmaceutical Company, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Type 1 Diabetes
Interventions: Insulin; Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 12 Years to 30 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Postprandial Glycemia, Metabolic Stress, Cognitive Change, Satisfaction, Personal
Interventions: Honey, Sucrose, Honey plus almonds, Sucrose plus almonds; Other
Lead sponsor: USDA, Western Human Nutrition Research Center; Federal
Eligibility: 18 Years to 40 Years
Enrollment: 58 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Davis, California

Conditions: Type 1 Diabetes Mellitus
Interventions: Humalog, Humulin-R, Recombinant human hyaluronidase PH20 (rHuPH20), Liquid meal; Drug · Other
Lead sponsor: Halozyme Therapeutics; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: Pre-diabetes
Interventions: Sitagliptin, Placebo; Drug · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 35 Years to 70 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Diabetes Mellitus, Type 2
Interventions: insulin glulisine, insulin glargine; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 345 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Healthy, Body Mass Index, Normal, Postprandial Hyperglycemia
Interventions: Alpha galactosidase, Placebo; Dietary Supplement
Lead sponsor: Iowa State University; Other
Eligibility: 21 Years to 34 Years
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Ames, Iowa

Conditions: Metabolic Syndrome, Inflammation, Hypertriglyceridemia, Obesity
Interventions: Aronia berry juice, Sham comparator; Dietary Supplement · Other
Lead sponsor: Montana State University; Other
Eligibility: 18 Years to 55 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Bozeman, Montana

Conditions: Postprandial Blood Glucose
Interventions: arabinogalactan; Other
Lead sponsor: Biofortis, Merieux NutriSciences; Industry
Eligibility: 21 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Addison, Illinois

Conditions: Type 1 Diabetes Mellitus
Interventions: Viaject 7, LISPRO; Drug
Lead sponsor: Biodel; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Healthy, Healthy Volunteer, Healthy Volunteers, Healthy Adult, Healthy Male and Female Subjects, Healthy Subjects, Healthy Volunteers Only, Healthy Non-smokers
Interventions: Negative control, Avocado, Fat and fiber addition; Other
Lead sponsor: University of Vermont Medical Center; Other
Eligibility: 21 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Burlington, Vermont

Conditions: Diabetes Mellitus, Type 2, PreDiabetes
Interventions: Dietary intervention; Other
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Stanford, California

Conditions: Diabetes Mellitus, Type 2
Interventions: GEM; Behavioral
Lead sponsor: University of Virginia; Other
Eligibility: 24 Years to 80 Years
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Type 1 Diabetes, Type 2 Diabetes
Interventions: Meal-Tagging App and Web-based Portal:, Fitness Tracker; Other · Device
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 25 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 2
States / cities: Boston, Massachusetts • Chapel Hill, North Carolina

Conditions: Type 1 Diabetes Mellitus
Interventions: insulin glulisine, insulin aspart; Drug
Lead sponsor: Corewell Health West; Other
Eligibility: 4 Years to 11 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Grand Rapids, Michigan

Conditions: Obesity, Type 2 Diabetes Mellitus, Insulin Resistance
Interventions: Not listed
Lead sponsor: Boston Medical Center; Other
Eligibility: 21 Years to 64 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Type 1 Diabetes
Interventions: ePID closed loop system, hyaluronidase, Lispro-PH20; Device · Drug
Lead sponsor: Yale University; Other
Eligibility: 12 Years to 40 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Healthy, Cardiovascular Disease, Atherogenic Dyslipidemia, Insulin Resistance
Interventions: Dietary Intervention; Other
Lead sponsor: UCSF Benioff Children's Hospital Oakland; Other
Eligibility: 20 Years and older
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 2
States / cities: Berkeley, California • Oakland, California

Conditions: Prediabetes
Interventions: Glucose, Glucose with Non-fat Milk, Glucose with Whey Protein Isolate, Glucose with Sodium Caseinate; Other
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years to 50 Years
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Hyperglycemia, Hypertension
Interventions: AVACEN 100, AVACEN 100 Heat Only, AVACEN Sham; Device
Lead sponsor: Jeff Moore; Other
Eligibility: 18 Years to 40 Years
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: San Diego, California

Conditions: Hyperinsulinemic Hypoglycemia
Interventions: Exenatide, Acarbose, Exenatide Placebo, Acarbose Placebo; Drug
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 60 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Type 2 Diabetes
Interventions: Nateglinide; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 78 Years
Enrollment: 28 participants
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Metabolic Syndrome, Obesity
Interventions: High-fat shake; Other
Lead sponsor: Oklahoma State University; Other
Eligibility: 18 Years to 50 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Stillwater, Oklahoma

Search by objective public record fields.

Emotion-Diet Interactions in Pregnancy

A Study to Evaluate the Effect of Nasal Insulin on Postprandial Glycemic Control in Type 2 Diabetic Patients

Timing of Meal Insulin Boluses for Optimal Postprandial Glycemic Control in Type 1 Diabetes

WHNRC (Western Human Nutrition Research Center) Honey Study

Phase II Pharmacokinetics Study of Humalog and Humulin-R With and Without rHuPH20 in Type 1 Diabetes Mellitus

Incretins in Impaired Fasting Glucose

Insulin Glulisine Administered Pre-meal Versus Post-meal in Adult Subjects With Type 2 Diabetes Mellitus Receiving Insulin Glargine as Basal Insulin

Glycemic Response of Whole Beans and Bean Products

Impacts of Aronia on Inflammation and the Gut Microbiome

Effect of an Arabinogalactan Product

To Evaluate the Effect on Post-prandial Glycemia Safety, and Tolerability of Viaject 7 vs. Lispro Insulin During Subcutaneous Insulin Pump Therapy

Avocado and Postprandial Responses

Prediabetes Stratification by Multi-omics Profile After Food Intake

Lifestyle Modification for Type 2 Diabetes Involving Reduction of After-meal Blood Glucose Elevations

A Study of Glucose Control in Participants With Type 1 and Type 2 Diabetes

The Effect of Insulin Glulisine Compared With Insulin Aspart on Breakfast Post Prandial Glucose Levels in Prepubertal Children

A Study to Examine Changes in GIP Plasma Levels Following Gastric Bypass Surgery in Obese Patients

Acceleration of Insulin Action by Hyaluronidase During Closed-Loop Therapy

Resistant Starch Insulin Sensitivity Trial

Regulation of Postprandial Nitric Oxide Bioavailability and Vascular Function By Dairy Milk

AVACEN Hand Heating on Fasting Blood Glucose

Evaluating Exenatide for the Treatment of Postprandial Hyperinsulinemic Hypoglycemia

Safety and Efficacy of Nateglinide in Patients With Type 2 Diabetes Already Taking Insulin Glargine, Metformin and/or Pioglitazone or Rosiglitazone

Identification of Early Cardiovascular Disease Risk Factors in Normal-weight Obesity